p110a PI3K inhibitor selective for p110 isoform activated in HER2+ breast cancers and gastric cancers. It inhibits proliferation of breast cancer cells and decreases invasiveness of squamous cell lung cancer cells. (C08-0488-459)

Thomas Scientific

Catalog No.: C08-0488-459
Manufacturer No.: B9700-1 mg
Manufacturer Name: LKT Laboratories, Inc
Quantity: 1
Unit of Measure: EA

Price: $126.53

List Price: $140.59

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account.

Current Stock:

Quantity:

Adding to cart… The item has been added

Description
Specifications

BYL-719 is an ATP-competitive oral PI3K inhibitor selective for the p110a isoform that is activated by a mutant PIK3CA gene in HER2+ breast cancers and gastric cancers. BYL-719 exhibits anticancer chemotherapeutic activity and inhibits proliferation in a variety of cell lines. IGF1 and neuregulin 1 activate mTOR, a downstream target of PI3K that mediates resistance to BYL-719 in some in vitro cancer models. This compound also decreases invasion and epithelial-to-mesenchymal transition (EMT) in cellular and animal models of squamous cell lung cancer. Grades: ≥99%, ≥99%ee

UPC:: 41122409
Condition:: New
Availability:: 3 Days
Weight:: 1.00 Ounces
HazmatClass:: No
WeightUOM:: LB
MPN:: B9700-1 mg
CAS:: 1217486-61-7

Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.

"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."